Publications scientifiques en 2019

Depuis le 31/03/2025
  1. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: a retrospective database study in France.
    Devillier P, Molimard M, Ansolabehere X, Bardoulat I, Coulombel N, Maurel F, Le Jeunne P, Demoly P.
    Allergy. 2019
  2. Real-life benefits of statins for cardiovascular prevention in elderly subjects: a population-based cohort study.
    Bezin J, Moore N, Mansiaux Y, Steg PG, Pariente A.
    Am J Med. 2019
  3. Pharmacoepidemiology, the new paradigm of drug evaluation.
    Bégaud B, Montastruc JL.
    Therapie. 2019
  4. Health administrative data enrichment using cohort information: Comparative evaluation of methods by simulation and application to real data.
    Silenou BC, Avalos M, Helmer C, Berr C, Pariente A, Jacqmin-Gadda H.
    2019. 2019
  5. Pharmacoepidemiology of statins.
    Bezin J, Moore N.
    Therapie. 2019
  6. Educational intervention to improve the knowledge, attitude and practice of healthcare professionals regarding pharmacovigilance in South-South Nigeria.
    Opadeyi AO, Fourrier-Réglat A, Isah AO.
    Ther Adv Drug Saf. 2019
  7. The French Levothyrox® crisis: We did the best we could but….
    Mouly S, Roustit M, Bagheri H, Perault-Pochat MC, Molimard M, Bordet R.
    Therapie. 2019
  8. Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections.
    Prevel R, Berdaï D, Boyer A.
    JAMA. 2019
  9. Methods in pharmacoepidemiology.
    Sommet A, Pariente A.
    Therapie. 2019
  10. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.
    Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, Lapeyre-Mestre M.
    Therapie. 2019
  11. Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life.
    Gouverneur A, Bezin J, Jové J, Bosco-Lévy P, Fourrier-Réglat A, Noize P.
    J Am Geriatr Soc. 2019
  12. Hepatitis B vaccination and central demyelination - History, description and observed/expected analyses of 624 cases reported to the French pharmacovigilance over a 20-year period.
    Mouchet J, Bégaud B.
    Vaccine. 2019
  13. Safety of levonorgestrel 52mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P, Gouverneur A, Langlade C, Miremont G, Pariente A.
    Contraception. 2019
  14. Six-year survival study after myocardial infarction: The EOLE prospective cohort study. Long-term survival after MI.
    Droz-Perroteau C, Blin P, Dureau-Pournin C, Thomas D, Danchin N, Tricoire J, Paillard F, Hercberg S, Guize L, Guiard E, Maïzi H, Bernard MA, Bénichou J, Moore N.
    Therapie. 2019
  15. Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.
    Massin P, Creuzot-Garcher C, Kodjikian L, Girmens JF, Delcourt C, Fajnkuchen F, Glacet-Bernard A, Guillausseau PJ, Ponthieux A, Blin P, Grelaud A.
    Ophthalmic Res. 2019
  16. A review of Algerian medicinal plants used in the treatment of diabetes.
    Hamza N, Berke B, Umar A, Cheze C, Gin H, Moore N.
    J Ethnopharmacol. 2019
  17. Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study.
    Létinier L, Cossin S, Mansiaux Y, Arnaud M, Salvo F, Bezin J, Thiessard F, Pariente A.
    Front Pharmacol. 2019
  18. What we know about media communication on antibiotics and antimicrobial resistance: A systematic review of the scientific literature.
    Catalán-Matamoros D, Pariente A, Elías-Pérez C.
    Patient Educ Couns. 2019
  19. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G, Billionnet C, Drouin J, Weill A, Neumann A, Pariente A.
    BMJ Open. 2019
  20. Appropriateness of psychotropic drug prescriptions in the elderly: structuring tools based on data extracted from the hospital information system to understand physician practices.
    Petit-Monéger A, Jouhet V, Thiessard F, Berdaï D, Noize P, Gilleron V, Caridade G, Salmi LR, Saillour-Glénisson F.
    BMC Health Serv Res. 2019
  21. The sustainable impact of an educational approach to improve the appropriateness of laboratory test orders in the ICU.
    Clouzeau B, Caujolle M, San-Miguel A, Pillot J, Gazeau N, Tacaille C, Dousset V, Bazin F, Vargas F, Hilbert G, Molimard M, Gruson D, Boyer A.
    PLoS One. 2019
  22. Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.
    Guiard E, Lelievre B, Rouyer M, Zerbib F, Diquet B, Mégraud F, Tison F, Bignon E, Lassalle R, Droz-Perroteau C, Moore N, Blin P.
    Drug Saf. 2019
  23. Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system.
    Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E.
    Acta Diabetol. 2019
  24. Ticagrelor and central sleep apnoea: Impact of withdrawal and reintroduction.
    Puel V, Théophile H, Godard I, Raymond N, Miremont-Salamé G, Gosse P, Pépin JL, Pariente A.
    Br J Clin Pharmacol. 2019
  25. Adverse events reported for levonorgestrel-releasing IUD Mirena® in France and impact of media coverage.
    Langlade C, Gouverneur A, Bosco-Lévy P, Gouraud A, Pérault-Pochat MC, Béné J, Miremont-Salamé G, Pariente A; French Network of Pharmacovigilance Centres.
    Br J Clin Pharmacol. 2019
  26. Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.
    Blin P, Dureau-Pournin C, Bénichou J, Cottin Y, Mismetti P, Abouelfath A, Lassalle R, Droz C, Moore N.
    Am J Cardiovasc Drugs. 2019
  27. Conventional mood stabilizers and/or second-generation antipsychotic drugs in bipolar disorders: A population-based comparison of risk of treatment failure.
    Tournier M, Neumann A, Pambrun E, Weill A, Chaffiol JP, Alla F, Bégaud B, Maura G, Verdoux H.
    J Affect Disord. 2019
  28. Comparative study of hypoglycaemia induced by opioids. Is it a class effect?
    Chrétien B, Dolladille C, Hamel-Sénécal L, Sassier M, Faillie JL, Miremont-Salamé G, Lelong-Boulouard V, Le Boisselier R, Fedrizzi S, Alexandre J, Humbert X.
    Expert Opin Drug Saf. 2019
  29. Incidence of Direct Oral Anticoagulant use in patients with non-valvular atrial fibrillation and characteristics of users in six European countries (2008-2015): A cross-national drug utilization study.
    Ibáñez L, Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Heeke A, Huerta C, Martin Merino E, Montero D, Leon-Muñoz LM, Gasse C, Moore N, Droz C, Lassalle R, Aakjaer M, Andersen M, De Bruin ML, Groenwold R, van den Ham R, Souverein P, Klungel O, Gardarsdottir H.
    Br J Clin Pharmacol. 2019
  30. Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.
    Blin P, Fauchier L, Dureau-Pournin C, Sacher F, Dallongeville J, Bernard MA, Lassalle R, Droz-Perroteau C, Moore N.
    Stroke. 2019
  31. The Reply.
    Bezin J, Moore N, Steg PG, Pariente A.
    Am J Med. 2019
  32. Secondary stroke prevention: a population-based cohort study on anticoagulation and antiplatelet treatments, and the risk of death or recurrence.
    Faure M, Castilloux AM, Lillo-Le-Louet A, Bégaud B, Moride Y.
    Clin Pharmacol Ther. 2019
  33. Reply to Letter to the Editor: hypoglycaemia and treatment with opioids.
    Chrétien B, Dolladille C, Hamel-Sénécal L, Sassier M, Faillie JL, Miremont-Salamé G, Lelong-Boulouard V, Le Boisselier R, Fedrizzi S, Alexandre J, Humbert X.
    Expert Opin Drug Saf. 2019
  34. Pharmacology and social media: Potentials and biases of web forums for drug mention analysis-case study of France.
    Audeh B, Calvier FE, Bellet F, Beyens MN, Pariente A, Lillo-Le Louet A, Bousquet C.
    Health Informatics J. 2019
  35. Pharmacovigilance - The next chapter.
    Moore N, Berdaï D, Blin P, Droz C.
    Therapie. 2019
  36. Pharmacological treatment patterns in heart failure: a population-based cohort study.
    Bosco-Lévy P, Favary C, Jové J, Lassalle R, Moore N, Droz-Perroteau C.
    Eur J Clin Pharmacol. 2019
  37. Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study.
    Fauchier L, Blin P, Sacher F, Dureau-Pournin C, Bernard MA, Lassalle R, Droz-Perroteau C, Dallongeville J, Moore N.
    Europace. 2019
  38. Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
    Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, Potey C, Funck-Brentano C, Roden DM, Moslehi JJ, Salem JE.
    Arch Cardiovasc Dis. 2019
  39. Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution.
    Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E.
    Acta Diabetol. 2019
  40. Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study.
    Villa A, Molimard M, Bignon E, Martinez B, Rouyer M, Mathoulin-Pelissier S, Baldi I, Verdun-Esquer C, Canal-Raffin M.
    BMJ Open. 2019
  41. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
    Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Moore N; FUJI Investigators.
    Br J Cancer. 2019
  42. Association of Valproic Acid With Central Sleep Apnea Syndrome: Two Case Reports.
    Guichard K, Micoulaud-Franchi JA, McGonigal A, Coulon P, Sureau C, Ghorayeb I, Salvo F, Philip P.
    J Clin Psychopharmacol. 2019
  43. Pharmacoepidemiology.
    Moore N, Blin P, Droz C.
    Handb Exp Pharmacol. 2019